Arrowhead files for regulatory clearance to begin Phase 1 study of ARO-ANG3
Arrowhead Pharmaceuticals announced that it has filed an application for approval to begin a Phase 1 clinical trial of ARO-ANG3, an RNAi-based investigational medicine targeting angiopoietin like protein 3 being developed for the treatment of dyslipidemias and metabolic diseases. ARO-ANG3 will be the fourth therapeutic candidate to enter clinical studies that leverages Arrowhead's Targeted RNAi Molecule platform. Pending approval, Arrowhead intends to proceed with AROANG1001, a Phase 1 single and multiple dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic effect of ARO-ANG3 in adult healthy volunteers and dyslipidemic patients. The study is designed to enroll up to 70 subjects. An application was submitted to an ethics committee in compliance with the Clinical Trial Notification process of the Australian Department of Health and Ageing, Therapeutic Goods Administration. As a reminder, Arrowhead will host a Research & Development Day to discuss ARO-ANG3 and its emerging pipeline of RNAi therapeutics that leverage the Company's proprietary Targeted RNAi Molecule platform on October 16, 2018 in New York City.